Materia and Sunesis Pharmaceuticals Enter Into Catalyst Licensing Agreement

Materia, Inc. and Sunesis Pharmaceuticals, Inc. have entered into a non-exclusive license agreement providing Sunesis access to Materia’s proprietary metathesis technology for use in...

PASADENA, CA and SOUTH SAN FRANCISCO, CA – April 2005. Materia, Inc. and Sunesis Pharmaceuticals, Inc. have entered into a non-exclusive license agreement providing Sunesis access to Materia’s proprietary metathesis technology for use in the synthesis of a compound under development. Terms of the agreement were not announced but grant Sunesis a license for catalyst use and access to collaborative services for their process optimization and specify supply terms for development quantities of specified Grubbs Catalysts.

“Enabled by the unique reactivity of the Grubbs Catalyst systems, we are seeing metathesis technology making significant inroads in the discovery and development of many new and important drug candidates in the pharmaceutical industry. We are pleased it is providing utility to Sunesis in their development of such an innovative treatment,” said Dr. Michael Giardello, Materia’s CEO and CTO.